Motus GI
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | - | 6.5m |
% growth | 197 % | (8 %) | 299 % | 51 % | (46 %) | - | - |
EBITDA | (23.4m) | (18.8m) | (18.1m) | (17.3m) | (11.1m) | - | - |
% EBITDA margin | (21899 %) | (19176 %) | (4619 %) | (2923 %) | (3488 %) | - | - |
Profit | (23.1m) | (19.3m) | (19.0m) | (18.6m) | (12.9m) | (10.6m) | (12.7m) |
% profit margin | (21576 %) | (19650 %) | (4868 %) | (3141 %) | (4034 %) | - | (197 %) |
EV / revenue | 429.9x | 188.9x | 30.8x | 2.2x | -0.5x | - | 0.8x |
EV / EBITDA | -2.0x | -1.0x | -0.7x | -0.1x | 0.0x | - | - |
R&D budget | 9.0m | 5.6m | 5.3m | 5.6m | 3.5m | - | - |
R&D % of revenue | 8423 % | 5668 % | 1366 % | 948 % | 1087 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$13.5m | Series A | ||
$30.0m | Late VC | ||
* | N/A | $17.5m Valuation: $77.9m 131.6x EV/LTM Revenues -6.0x EV/LTM EBITDA | IPO |
$8.0m | Post IPO Debt | ||
$12.0m | Post IPO Debt | ||
* | N/A | $5.0m | Post IPO Equity |
* | N/A | $2.7m | Post IPO Equity |
Total Funding | €39.5m |
Recent News about Motus GI
EditMotus GI Holdings, Inc. is a medical technology company focused on improving the quality and efficiency of colonoscopy procedures. The company's flagship product, the Pure Vu System, enhances visualization of the colon, enabling physicians to perform high-quality colonoscopies more effectively. This system is designed to be used in both inpatient and outpatient settings, targeting healthcare providers such as hospitals and clinics. Motus GI operates in the medical device market, with a business model centered around the sale and distribution of its Pure Vu System. Revenue is generated through direct sales to healthcare facilities and ongoing support services. The company aims to address the challenges of inadequate colon preparation, which can lead to incomplete procedures and the need for repeat colonoscopies. By improving visualization, the Pure Vu System helps reduce procedure times and improve patient outcomes, ultimately leading to cost savings for healthcare providers.
Keywords: colonoscopy, visualization, medical technology, Pure Vu System, healthcare, inpatient, outpatient, efficiency, patient outcomes, cost savings.